'Corporate Reputation of Pharma in 2018 - the Perspective of Neurological Patient Groups'

~ Contact: Alex Wyke ~ Tel: +44-(0)7960-855-019 ~ Email: report@patient-view.com

EMBARGO: London, September 9th, 2019 6AM GMT

ABOUT THIS REPORT AND SURVEY

This the 6th edition of 'The Corporate Reputation of Pharma — from the Perspective of Neurological Patient Groups'.
The 2018 results are drawn from a survey of patient groups, conducted November 2018 - February 2019.
Profile of 2018's respondent neurological patient groups
222 respondent neurological patient groups, including those specialising in: ● dementia [20], ● epilepsy [32], ● multiple sclerosis [45], ● Parkinson’s disease [29], and ● other neurological conditions [96].
The 222 neurological patient groups are from 45 countries, with the largest numbers coming from ● Spain [31], ● the United States [26], and ● the United Kingdom [14].
55% are national patient groups. 8% are international patient groups.
Patient-group partnerships with industry: 55% of the 222 respondent neurological patient groups worked/partnered with at least one pharma company.
Company analyses: the following 30 pharma companies were analysed by the 222 neurological patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation:

The 2018 'Corporate-Reputation' neurological report contains four appendices:

Appendix I. Analyses of corporate reputation in the field of epilepsy, 2018 v. 2017.
Appendix II. Analyses of corporate reputation in the field of multiple sclerosis, 2018 v. 2017.
Appendix III. Analyses of corporate reputation in the field of Parkinson's disease, 2018 v. 2017.

And ...

Appendix IV: Comments from 2018's respondent neurological patient groups on how pharma can improve (organised by country and condition).

KEY FINDINGS ACROSS THE PHARMA INDUSTRY

The corporate reputation of the pharmaceutical industry, 2013-2018. Percentage of respondent neurological patient groups each year stating “Excellent” or “Good”

The 222 neurological patient groups worldwide responding to the 2018 'Corporate Reputation of the Pharmaceutical Industry' survey were more negative about the industry’s corporate reputation than their predecessor respondents in 2017. A total of 37% of 2018’s 222 neurological patient groups stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation in 2018—ranking the industry 4th for corporate reputation out of nine healthcare sectors (compared with 3rd in 2017). However, the chart above shows just how sentiment about the industry has fluctuated among neurological patient groups, year to year.

Percentage of respondent neurological patient groups, per year, stating that the pharmaceutical industry is “Excellent” or “Good” at providing high-quality useful products

One possible explanation for the industry’s fall in corporate reputation among neurological patient groups during 2018 is that these groups (and patients with a neurological condition) regard pharma’s ability to innovate, and to produce useful new neurological products, to be at its lowest since 2015.

The different categories of neurological patient groups take diverse attitudes to pharma's corporate reputation—although these patient groups unilaterally marked the industry down in 2018 [see chart below]. Nonetheless, the categories of neurological patient groups that are the most positive about pharma's ability to create useful, high-quality products are also those which rate the corporate reputation of the industry most highly.

Percentage of various categories of neurological patient groups stating that the pharmaceutical industry as a whole had an “Excellent” or “Good” corporate reputation, 2018 v. 2017

Percentage of various categories of neurological patient groups stating that the pharmaceutical industry as a whole was “Excellent” or “Good” at providing high-quality products useful to patients, 2018 v. 2017

Feedback received from 2018's respondent neurological patient groups indicates that many are concerned about both pricing and access to the innovative medicines which do happen to be available.

“Continue to focus on delivering real innovation, and not ‘me-too’ products. Companies also must address the price of innovative medicines in the US.”

—National neurological patient group, United States

“Keep the medication low tech, easily available, and easy to access for patients—unlike some of the new treatments, which are high tech, extremely expensive, and need the patient to be seen in more than just primary care.”

—National neurological patient group, Ireland

HOW DID COMPANIES PERFORM?

HOW CORPORATE REPUTATION IS MEASURED

The overall corporate reputation of each company is assessed according to that company's performance (as judged by neurological patient groups) at 12 individual indicators of corporate reputation.

The TOP-TEN companies for corporate reputation—from the perspective of neurological patient groups familiar with the company, 2018 v. 2017

The indicators [listed below] have been developed over the years by PatientView, drawing on recommendations from patient groups, health professionals, health regulators, and industry.

PatientView's 12 indicators used to assess pharma corporate reputation

1. Patient centricity.
2. Patient information.
3. Patient safety.
4. High-quality products.
5i. Transparency: pricing.
5ii. Transparency: clinical-trial data.

5iii. Transparency: funding of stakeholders.
6. Integrity.
7. Relationships with patient groups.
8. Providing services ‘beyond the pill’.
9i. Engaging patients in research.
9ii. Engaging patients in development.

UCB dominated the neurological corporate-reputation league tables for 2018, coming overall 1st out of 30 companies (as it did in 2017), and 1st for 7 of the 12 individual indicators of corporate reputation—according to the 46 respondent neurological patient groups familiar with the company.

Novartis came overall 2nd out of 30 companies for corporate reputation in 2018 (a rise of three places over 2017), according to the 147 respondent neurological patient groups familiar with the company. And ...
Merck KGaA/EMD Serono came overall 3rd out of 30 companies for corporate reputation in 2018 (a rise of one place over 2017), according to the 62 respondent neurological patient groups familiar with the company.
Biogen, Roche/Genentech, and Sanofi were all assessed by respondent neurological patient groups familiar with the companies as having jumped up two places in rank from 2017—coming in at overall 4th, 5th, and 6th, respectively, in 2018. Meanwhile ...

Acorda Therapeutics saw the biggest increase up the rankings, coming 9th out of 30 companies in 2018—up ten places from its 2017 position.

The EPILEPSY corporate-reputation rankings, 2018 [32 respondent epilepsy patient groups]

Companies ranking 1st out of 6 companies among epilepsy patient groups familiar with the company, 2018

UCB was ranked overall 1st for corporate reputation in 2018 by epilepsy patient groups familiar with the company

Patient centricity: UCB
Patient information: UCB
Patient safety: Eisai
High-quality products: UCB
Transparency/pricing: UCB
Transparency/clinical-trial data: UCB
Transparency/funding of stakeholders: UCB
Integrity: UCB
Relationships with patient groups: UCB
Providing services ‘beyond the pill’: UCB
Engaging patients in research: UCB
Engaging patients in development: UCB

The MULTIPLE-SCLEROSIS corporate-reputation rankings, 2018 [45 respondent MS patient groups]

Companies ranking 1st out of 8 companies among multiple-sclerosis patient groups familiar with the company, 2018

Sanofi was ranked overall 1st for corporate reputation in 2018 by multiple-sclerosis patient groups familiar with the company

Patient centricity: Sanofi
Patient information: Sanofi
Patient safety: Novartis
High-quality products: Merck KGaA/EMD Serono
Transparency/pricing: Sanofi
Transparency/clinical-trial data: Roche/Genentech
Transparency/funding of stakeholders: Sanofi
Integrity: Roche/Genentech
Relationships with patient groups: Sanofi
Providing services ‘beyond the pill’: Sanofi
Engaging patients in research: Roche/Genentech
Engaging patients in development: Novartis

The PARKINSON'S-DISEASE corporate-reputation rankings, 2018 [29 respondent Parkinson's patient groups]

Companies ranking 1st out of 6 companies among Parkinson's patient groups familiar with the company, 2018

AbbVie was ranked overall 1st for corporate reputation in 2018 by Parkinson's patient groups familiar with the company

Patient centricity: AbbVie
Patient information: AbbVie
Patient safety: AbbVie
High-quality products: AbbVie
Transparency/pricing: Lundbeck
Transparency/clinical-trial data: Lundbeck Transparency/funding of stakeholders: AbbVie
Integrity: AbbVie
Relationships with patient groups: AbbVie
Providing services ‘beyond the pill’: AbbVie
Engaging patients in research: Lundbeck
Engaging patients in development: Lundbeck

-END OF PRESS RELEASE-

For further information on the 2018 NEUROLOGICAL report, please use contact details at the top of this press release

~END OF PRESS RELEASE~